ロード中...
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We evaluated the efficacy and safety of t...
保存先:
| 出版年: | Leuk Res |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7787349/ https://ncbi.nlm.nih.gov/pubmed/31030089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2019.03.008 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|